Format

Send to

Choose Destination
Br J Cancer. 2013 Jan 15;108(1):222-8. doi: 10.1038/bjc.2012.492. Epub 2012 Nov 20.

Metabolic syndrome and hepatocellular carcinoma risk.

Author information

1
Istituto di Ricerche Farmacologiche Mario Negri, via G. La Masa 19, 20156 Milan, Italy.

Abstract

BACKGROUND:

Hepatocellular carcinoma (HCC) has been associated to diabetes and obesity, but a possible association with the metabolic syndrome (MetS) and its potential interaction with hepatitis is open to discussion.

METHODS:

We analysed data from an Italian case-control study, including 185 HCC cases and 404 controls. Odds ratios (ORs) and 95% confidence intervals (CIs) were computed from unconditional logistic regression models.

RESULTS:

Among the MetS components, diabetes and obesity (i.e, body mass index (BMI)≥30 kg m(-2)) were positively associated to HCC risk, with ORs of 4.33 (95% CI, 1.89-9.86) and 1.97 (95% CI, 1.03-3.79), respectively. The ORs for the MetS were 4.06 (95% CI, 1.33-12.38) defining obesity as BMI≥25, and 1.92 (95% CI, 0.38-9.76) defining it as BMI≥30. The risk increased with the number of MetS components, up to an almost four-fold excess risk among subjects with ≥2 MetS factors. Among subjects without chronic infection with hepatitis B and/or C, the OR for those with ≥2 MetS components was over six-fold elevated. There was no consistent association in subjects with serological evidence of hepatitis B and/or C infection.

CONCLUSION:

This study found that the risk of HCC increases with the number of MetS components in subjects not chronically infected with hepatitis viruses.

PMID:
23169288
PMCID:
PMC3553509
DOI:
10.1038/bjc.2012.492
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Nature Publishing Group Icon for PubMed Central
Loading ...
Support Center